Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends

Key Points

• The research aims to evaluate gender and geographic differences in industry payments to gynecologic oncologists and to identify trends across different therapeutic classes.
• Conducted a cross-sectional analysis using data from the CMS Open Payments database from 2018 to 2024.
• Included all physicians designated as gynecologic oncologists, aggregating payments by physician.
• Analyzed payments based on physician gender, geographic region, and state.
• Mapped drug-related payments to therapeutic classes specific to gynecologic oncology.
• Examined temporal trends descriptively.
• 75,382 industry payments totaling $33.4 million made to 2063 gynecologic oncologists with 55.9% females and 44.1% males.
• Males received higher median total payments ($863 vs. $312) and more payments (12 vs. 6).
• Highest total payments recorded in the South ($11.3 million), while mean payments were highest in the West ($390).
• PARP inhibitors peaked in 2019 but declined thereafter; payments for other therapies increased steadily.